Product liability and supply chains

The revised EU Product Liability Directive applies from December 2026 and forks liability on the date a batch reached the market: the new regime presumes defects, compels disclosure and can follow a lot for twenty-five years, while Swiss law under the PrHG diverges on the same facts. Upstream, the obligations have moved into the supply chain itself: the EU Pharma Package extends environmental-risk assessment across every manufacturing site an antimicrobial passes through, turns shortage prevention into standing law for the marketing authorization holder, and, for cell and gene therapy, brings human-origin starting materials under the SoHO Regulation up to the manufacturer's door. The analyses below trace that exposure from contamination liability through contractual allocation to the repapering of supply agreements a US sponsor now faces.

5 insights ยท latest June 2026

Insights on Product liability and supply chains

No. 48 Cross-Border

The EU Product Liability Directive Lands on US Pharma Supply Chains: Strict Liability, Presumed Defects, and a 25-Year Tail

Directive (EU) 2024/2853 applies from 9 December 2026, forking liability on the date a batch reached the market. The new regime presumes defects, compels disclosure, and can follow a lot for twenty-five years.

No. 04 High Stakes

Pharma Supply Chain Liability: When Contracts Meet Reality

Pharmaceutical contamination liability extends beyond the manufacturer. The revised EU PLD reshapes supply chain exposure from 2026; Swiss law diverges.

No. 36 Critical Compliance

Environmental Risk Assessment Reaches Across the Pacific: Supply-Chain ERA Obligations for US Manufacturers Using Asian APIs

The EU Pharma Package extends antimicrobial environmental-risk-assessment duties across the entire manufacturing supply chain, with authorisation refusal or revocation for unaddressed risk. US manufacturers relying on Asian API suppliers face new contractual exposure.

No. 45 Strategic Risk

The EU Pharma Package's Supply-Side Architecture: Critical-Medicines Coordination and Joint Cross-Border Procurement for US Sponsors

The EU Pharma Package's Regulation side turns shortage prevention into standing law: a Union critical-medicines list, prevention plans, contingency stocks, and joint cross-border procurement. The duties attach to the marketing authorization holder, often a US sponsor's EU distributor.

No. 60 Emerging Issue

The SoHO Regulation Reaches Cell and Gene Therapy: New EU Rules on Substances of Human Origin for US Biotech

From 7 August 2027 the SoHO Regulation replaces the Blood and Tissues and Cells Directives, extending EU oversight of human-origin starting materials up to the manufacturer's door and requiring US cell and gene therapy sponsors to repaper supply agreements.

Good questions deserve specific answers.

Get in Touch